Trevi Therapeutics Announces Additions to the Senior Management Staff
Key Management Appointments Aid Enterprise Advancement as Guide Trials Transfer Towards Data
NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-phase biopharmaceutical organization targeted on the growth and commercialization of the investigational treatment Haduvio™ (nalbuphine ER) to treat significant neurologically mediated ailments, now declared the appointment of Lisa Delfini, CPA, as Chief Monetary Officer and Danine Summers, as Vice President, Professional medical Affairs. Ms. Delfini will guide the accounting and finance functions. Ms. Summers will be liable for educating the professional medical group on Haduvio’s facts and growth systems via publications, congresses and partnership setting up with essential feeling leaders.
New CFO and Vice President, Health-related Affairs will be instrumental in Trevi’s expansion as guide trials go in the direction of knowledge
“We are thrilled to welcome Lisa and Danine to our competent senior leadership staff,” explained Jennifer L. Fantastic, President and Main Executive Officer of Trevi. “Their expertise and experience will be instrumental as we transfer in direction of enrollment completion and topline details in our Period 2b/3 PRISM trial and Period 2 CANAL demo and planning for the future phase of development at Trevi.”
Ms. Delfini joins Trevi with 30 several years of expertise in the money sector. Her track record incorporates helping community and private providers with finance transformation and getting ready for and executing money boosting routines, acquisitions, and other advanced economic and accounting issues. As a Fiscal Accounting and Advisory Expert services Spouse at Marcum LLP, Ms. Delfini led a group of pros who presented advisory products and services on monetary activities to corporations. In this job, she served as interim CFO, CAO or controller for organizations in multiple sectors, such as prescribed drugs. Beforehand, Ms. Delfini labored at General Electric exactly where she was the Worldwide Controller for the GE Company Technological Heart of Excellence (TCOE) and then became the World Controller for GE Industrial Solutions. Ms. Delfini started her career at Deloitte & Touche LLP wherever she labored for 16 years and done her time there as a Customer Support Partner. She holds a B.S. in Accounting from Lehigh University and is a Certified Community Accountant in the State of Connecticut.
Ms. Summers is an accomplished Health care Affairs executive whose results in main health-related affairs operations, critical feeling chief communication and new industry improvement spans during start off-up, progress, turnaround, and acquisition phases. Ms. Summers has expended the bulk of her profession doing work in dermatology-centered providers. Right before joining Trevi, she held varying senior administration roles in medical affairs and promoting at providers these types of as Anacor Pharmaceuticals, Menlo Therapeutics, Medicis Pharmaceutical, Connetics Company, VICOM/FCB and Roche Prescription drugs. Ms. Summers was instrumental in the progress of Health-related Affairs departments and shown her capacity to link with health care gurus to educate them on their products’ profiles. Ms. Summers retains an M.B.A. in Advertising and marketing from the Golden Gate University and a B.A. in Psychology, Enterprise Minimal from San Jose State University.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a medical-phase biopharmaceutical organization centered on the improvement and commercialization of the investigational remedy Haduvio to address serious neurologically mediated situations. Trevi is conducting a Phase 2b/3 medical trial of Haduvio for the treatment of long-term pruritus connected with prurigo nodularis (PN) and a Phase 2 trial for serious cough in individuals with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a prevalent pathophysiology that is mediated via opioid receptors in the central and peripheral anxious systems.
Started in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
About Haduvio
Haduvio, an investigational therapy, is an oral extended-launch formulation of nalbuphine. Nalbuphine is a combined ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been accepted and marketed as an injectable for suffering indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are recognized to be crucial mediators of itch, cough and selected movement ailments. Nalbuphine’s system of action may perhaps also mitigate the danger of abuse linked with µ-opioid agonists since it antagonizes, or blocks, µ-opioid receptors. Parenteral nalbuphine is not at present categorized as a controlled compound by the DEA in the United States and by regulatory authorities in most of Europe. Trevi intends to suggest Haduvio as the trade title for nalbuphine ER. Haduvio is an investigational remedy that has been granted Quick Keep track of designation by the Food and drug administration for the proposed sign of reduction of reasonable to serious pruritus in people with PN. Its security and efficacy have not been evaluated by any regulatory authority.
Forward-Hunting Statements
Statements contained in this push launch concerning matters that are not historical specifics are “ahead-searching statements” in just the meaning of the Non-public Securities Litigation Reform Act of 1995. These types of statements are topic to hazards and uncertainties and genuine success may perhaps differ materially from people expressed or implied by this sort of forward-hunting statements. This kind of statements involve, but are not restricted to, statements with regards to Trevi’s business enterprise programs and objectives, which includes future plans or anticipations for Trevi’s merchandise candidates, and other statements that contains the words “believes,” “anticipates,” “ideas,” “expects,” and comparable expressions. Pitfalls that contribute to the unsure nature of the forward-looking statements involve: uncertainties regarding the good results, cost and timing of Trevi’s item prospect advancement routines and ongoing and prepared scientific trials uncertainties concerning the scope, timing and severity of the COVID-19 pandemic, the effects of the COVID-19 pandemic on Trevi’s clinical operations and actions taken in reaction to the pandemic uncertainties with regards to Trevi’s skill to execute on its technique the danger that beneficial success from a medical trial may perhaps not necessarily be predictive of the outcomes of foreseeable future or ongoing clinical trials prospective regulatory developments in the United States and international international locations uncertainties relating to rapidly monitor designation and the result such standing could have on the regulatory evaluation or approval method uncertainties inherent in estimating Trevi’s money runway, long term bills and other economic benefits, such as Trevi’s skill to carry on as a heading worry and its obligations underneath its loan facility as very well as other hazards and uncertainties established forth in the quarterly report on Variety 10-Q for the quarter finished March 31, 2021 submitted with the Securities and Exchange Fee and in subsequent filings with the Securities and Trade Commission. All forward-on the lookout statements contained in this press launch talk only as of the day on which they have been created. Trevi undertakes no obligation to update this sort of statements to replicate events that occur or circumstances that exist right after the day on which they had been created.
Investor Speak to
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
[email protected]
Media Get hold of
Rosalia Scampoli
914-815-1465
[email protected]
Perspective first articles to obtain multimedia:https://www.prnewswire.com/information-releases/trevi-therapeutics-announces-additions-to-the-senior-leadership-staff-301351400.html
Source Trevi Therapeutics, Inc.